Related Experiment Video
Updated: Aug 15, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Combination therapy of resistant warts in a patient with AIDS
1Department of Dermatology, University of Texas Southwestern Medical Center, Dallas 75235-9069, USA.
Background:
An AIDS patient on anti-HIV therapy consisting of two reverse transcriptase inhibitors had a low CD4+ lymphocyte count, a high HIV viral RNA load, and facial warts that were resistant to ablative therapy.
Objective:
To find a regimen to treat resistant warts in an AIDS patient with a depressed CD4 count and high HIV viral load.
Methods:
A protease inhibitor was added to his regimen and he was treated with ablative therapy using a 585 nm flashlamp-pumped pulsed dye laser (FPPDL).
Results:
Observed resolution of the warts one month later, with no recurrence at seven-month follow-up.
Conclusions:
Treatment of resistant warts in patients with AIDS may be enhanced by triple-drug therapy which includes a protease inhibitor, used in combination with ablative therapy, such as the FPPDL.
Related Concept Videos
Retrovirus Life Cycles
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Cryptococcal Meningitis
Antiviral Nucleoside Inhibitors

